文献速递膀胱癌与上尿路尿路上皮癌

优化临床阳性区域淋巴结上尿路尿路上皮癌的化疗顺序

Optimizing the Sequence of Chemotherapy for Upper Tract Urothelial Carcinoma with Clinically Positive Regional Lymph Nodes.
PubMed 文献 · J Urol · 2019-06-07

基于美国国家癌症数据库1658例cN+M0上尿路尿路上皮癌患者,比较不同治疗顺序的生存。术前化疗仅占6.8%,中位总生存36个月,高于辅助化疗21个月、单纯化疗14个月、单纯手术10个月和无治疗5个月。多因素分析示术前化疗较辅助化疗改善总生存(HR 0.58,95%CI 0.38-0.87)。

要点

  • 术前化疗仅占6.8%,中位总生存36个月,为各组最高。
  • 术前化疗较辅助化疗改善总生存(HR 0.58,95%CI 0.38-0.87)。
  • 术前化疗组pN0达34.6%,初始手术组仅10.3%。

核心结论

  • 术前化疗是cN+M0上尿路尿路上皮癌最少采用的治疗策略,但与最高的中位总生存相关。
  • 单纯化疗组与单纯手术组之间生存无统计学显著差异。
  • 总体结果提示,在可行时初始化疗对该人群是合适的。

研究设计与样本

  • 回顾性分析美国国家癌症数据库(NCDB)中1658例cN+M0上尿路尿路上皮癌患者,按治疗分组比较基线特征,并用多因素Cox回归模型完成生存分析。

主要发现

  • 术前化疗组占总体6.8%,中位总生存36个月;辅助化疗组21个月;单纯化疗组14个月;单纯手术无围手术期化疗组10个月;无治疗组5个月。
  • 多因素分析中,术前化疗组较辅助化疗组改善中位总生存(HR 0.58,95%CI 0.38-0.87)。
  • 单纯化疗组与单纯手术组之间生存无统计学显著差异。
  • 术前化疗组34.6%达到pN0,而初始手术组为10.3%。

临床怎么用

  • 作者认为,在可行时初始化疗对该人群是合适的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Upper tract urothelial carcinoma with clinically positive regional lymph nodes is an aggressive disease state with a high propensity for metastasis and death. The current literature is limited regarding national practice patterns and outcomes in this patient population. MATERIALS AND METHODS: We identified 1,658 patients in the NCDB (National Cancer Database) who had cN+M0 upper tract urothelial carcinoma. Patients were stratified into treatment groups. We compared baseline patient and tumor characteristics between the groups, and completed survival analysis using a multivariate Cox regression model. RESULTS: There were 1,658 patients in the final study population. Preoperative chemotherapy was the least performed treatment. That group comprised 6.8% of the overall population and was associated with the highest median overall survival of 36 months compared to 21 months for adjuvant chemotherapy, 14 for chemotherapy only, 10 for surgery without perioperative chemotherapy and 5 for no treatment. On multivariate analysis preoperative chemotherapy was associated with improved median overall survival compared to that in the adjuvant chemotherapy group (HR 0.58, 95% CI 0.38-0.87). There was no statistically significant difference in survival between the chemotherapy only and the surgery only groups. Of patients in the preoperative chemotherapy group 34.6% achieved pN0 status compared to 10.3% of those who underwent surgery as initial therapy. CONCLUSIONS: Preoperative chemotherapy was the least performed treatment strategy in the management of cN+M0 upper tract urothelial carcinoma but it was associated with the highest median overall survival. There was no difference in survival between the chemotherapy only and the surgery only groups. Overall these results suggest that initial chemotherapy is appropriate in this population when feasible.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Chakiryan N, Martinez A, Gao L, et al. Optimizing the Sequence of Chemotherapy for Upper Tract Urothelial Carcinoma with Clinically Positive Regional Lymph Nodes. J Urol. 2019. PMID: 30925108. doi:10.1097/JU.0000000000000172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。